Synthesis and in vitro evaluation of two progressive series of bifunctional polyhydroxybenzamide catechol-O-methyltransferase inhibitors

Journal of Medicinal Chemistry

Volumn 40, Issue 13, 1997, Pages 2035-2039

  Brevitt, Sharon E ^a   Tan, Eng Wui ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; N,N' 1,3 PROPANEDIYLBIS(3,4 DIHYDROXYBENZAMIDE); N,N' 1,3 PROPANEDIYLBIS(3,4,5 TRIHYDROXYBENZAMIDE); PROPYLAMINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; NONHUMAN; SWINE;

ANIMALS; BENZAMIDES; CATECHIN; CATECHOL O-METHYLTRANSFERASE; CROSS-LINKING REAGENTS; ENZYME INHIBITORS; LIVER; MODELS, CHEMICAL; NORDIHYDROGUAIARETIC ACID; PAPAVERINE; SWINE;

EID: 0030905894     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9605187     Document Type: Article

References (41)

1. Schultz, E.; Tarpila, S.; Backström, A. C.; Gordin, A.; Nissinen, E.; Pohto, P. Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone. Eur. J. Clin. Pharmacol. 1991, 40, 577-580.
2. Guldberg, H.; Marsden, C. Catechol-O-methyltransferase: pharmacological aspects and physiological role. Pharmacol. Rev. 1975, No. 2, 135-206. 206.
3. Guattari, B. High-performance liquid chromatographic determination with ultraviolet detection of S-adenosyl-L-methionine and S-adenosyl-L-homocysteine in rat tissues and simultaneously of normetanephrine and metanephrine for phenylethanolamine-N-methyltransferase or catechol-O-methyltransferase. J. Chromatogr. 1991, 567, 254-260.
4. Axelrod, J.; Tomchick, R. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 1958, 233 (3), 702-705.
5. Borchardt, R. T.; Cheng, C. F. Purification and characterization of rat heart and brain catechol methyltransferase activities. Biochim. Biophys. Acta 1978, 522, 49-62.
6. Borchardt, R. T.; Thakker, D. R. Affinity labeling of catechol-O-methyltransferase by N-haloacetyl derivatives of 3, 5-dimethoxy-4-hydroxyphenylethylamine and 3,4-dimethoxy-5-hydroxyphenylethylamine. Kinetics of inactivation. Biochemistry 1975, 14, 4542-4551.
7. Burba, J. V.; Becking, G. C. Effect of the antioxidant norhydroguaiaretic acid on the in vitro activity of catechol-O-methyltransferase. Arch. Int. Pharmacodyn. Ther. 1969, 180, 323-329.
8. Cedarbaum, J. M. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin. Pharmokinet. 1987, 13, 141-178.
9. Männistö, P. T.; Kaakola, S. New selective COMT inhibitors: useful adjuncts for Parkinson's disease. Trends Pharmacol. Sci. 1989, 10, 54-56.
10. Cedarbaum, J. M.; Leger, G.; Guttom, M. Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Clin. Neuropharmacol. 1991, 14 (4), 330-342.
11. Booth, A. N.; Masri, M. S.; Robins, D. J.; Emerson, O. H.; Jones, F. T.; Deeds, F. The metabolic fate of gallic acid and related compounds. J. Biol. Chem. 1959, 234 (11), 3014-3016.
12. Calne, D. B.; Sandler, M. L-Dopa and Parkinsonism. Nature 1970, 226, 21-24.
13. Wade, L. A.; Katzman, R. 3-O-methyldopa inhibition of L-dopa at the blood brain barrier. Life Sci. 1975, 17, 131-136.
14. Wade, L. A.; Katzman, R. Synthetic amino acids and the nature of L-dopa transport at the blood-brain barrier. J. Neurochem. 1975, 25, 837-842.
15. Kuruma, I.; Bartholini, G.; Tissot, R.; Pletscher, A. The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin. Pharmacol. Ther. 1971, 12, 678-682.
16. Wylie, D. W.; Archer, S.; Arnold, A. Augmentation of pharmacological properties of catecholamines by O-methyltransferase inhibitors. J. Pharmacol. Exp. Ther. 1960, 130, 239-244.
17. Crout, J. R. Inhibition of catechol-O-methyltransferase by pyrogallol in the rat. Biochem. Pharmacol. 1961, 6, 47-54.
18. Ross, S. B.; Haljasmaa, Ø. Catechol-O-methyltransferase inhibitors. In vitro inhibition of the enzyme in mouse-brain extract. Acta Pharmacol. Toxicol. 1964, 21, 205-214.
19. Belleau, B.; Burba, J. Tropolones: a unique class of potent non-competitive inhibitors of S-adenosylmethionine-catechol methyltransferase. Biochim. Biophys. Acta 1961, 54, 195-196.
20. Keränen, T.; Gordin, A.; Harjola, V. P.; Karlsson, M.; Korpela, K.; Pentikainen, P. J.; Rila, H.; Seppälä, L.; Wikberg, T. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin. Neuropharmacol. 1993, 16 (12), 145-156.
21. Männistö, P. T.; Kaakkola, S.; Nissinen, E.; Linden, I. B.; Pohto, P. Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci. 1988, 43, 1465-1471.
22. Männistö, P. T.; Kaakkola, S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol. Toxicol. 1990, 66, 317-323.
23. Wikberg, T.; Taskinen, J. Determination of catechol-O-methyltransferase inhibitor, nitecapone, in human plasma and urine by high-performance liquid chromatography. J. Pharm. Biomed. Anal. 1991, 9 (1), 59-64.
24. Linden, I. B.; Nissinen, E.; Etemadzadeh, E.; Kaakkola, S.; Männistö, P. T.; Pohto, P. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease. J. Pharmacol. Exp. Ther. 1988, 247 (1), 289-293.
25. Roberts, J. W.; Cora-Locatelli, G.; Braui, D.; Amantea, M. A.; Mouradian, M. M.; Chase, T. N. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in Parkinsonian patients. Neurology 1993, 43 (12), 2685-2688.
26. Merello, M.; Lees, A. J.; Webster, R.; Borvingdon, M.; Gordin, A. The effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute L-dopa administration in patient with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 1994, 57, 186-189.
27. Kaakkola, S.; Teräväinen, H.; Ahtila, S.; Rita, H.; Gordin, A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in Parkinsonian patients. Neurology 1994, 44 (1), 77-80.
28. Keränen, T.; Gordin, A.; Karlsson, M.; Korpela, K.; Pentikäinen, P. J.; Rita, H.; Schultz, E.; Seppälä, L.; Wikberg, T. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur. J. Clin. Pharmacol. 1994, 46, 151-157.
29. Nutt, J. G.; Woodward, W. R.; Beckner, R. M.; Stone, C. K.; Berggren, K.; Carter, J. H.; Gancher, S. T.; Hammerstad, J. P.; Gordin, A. Effect of peripheral catechol-O-methytransferase (COMT) inhibitor on the pharmacokinetics of levodopa in Parkinsonian patients. Neurology 1994, 44 (5), 913-919.
30. Burba, J. V.; Murnaghan, M. F. Catechol-O-methyltransferase inhibition and potentiation of epinephrine responses by desmethylpapaverine. Biochem. Pharmacol. 1966, 14, 823-829.
31. Bäckström, P.; Honkanen, E.; Pippuri, A.; Kairisalo, P.; Pystynen, J.; Heinola, K.; Nissinen, E.; Linden, I. B.; Männistö, P. T.; Kaakola, S.; Pohto, P. Synthesis of some novel potent and selective catechol-O-methyltransferase (COMT) inhibitors. J. Med. Chem. 1989, 32, 841-846.
32. Borgulya, J.; Burderer, H.; Bernauer, K.; Zurcher, G.; Prada, M. D. Catechol-O-methyltransferase-inhibiting pyrocatechol derivatives-synthesis and structure activity studies. Helv. Chim. Acta 1989, 72, 952-968.
33. Nissinen, E.; Linden, I. B.; Schultz, E.; Kaakkola, S.; Männistö, P. T.; Pohto, P. Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat. Eur. J. Pharmacol. 1988, 153, 263-269.
34. Pérez, R. A.; Fernández-Alvarez, E.; Nieto, O.; Piedrafita, F. J. Dihydroxynitrobenzaldehydes and Hydroxymethoxynitrobenzaldehydes: Synthesis and Biological Activity as Catechol-O-methyltransferase Inhibitors. J. Med. Chem. 1992, 35, 4584-4588.
35. Rebek, J.; Feitler, D. An Improved Method for the Study of Reaction Intermediates. The Mechanism of Peptide Synthesis Mediated by Carbodiimides. J. Am. Chem. Soc. 1973, 95, 4052-4053.
36. Rebek, J.; Feitler, D. Mechanism of the Carbodiimide Reaction. II. Peptide Synthesis on the Solid Phase. J. Am. Chem. Soc. 1974, 96, 1606-1607.
37. Sheehan, J. C.; Hess, G. P. A New Method of Forming Peptide Bonds. J. Am. Chem. Soc. 1955, 77, 1067-1068.
38. Belleau, B.; Malek, G. A New Convenient Reagent for Peptide Synthesis. J. Am. Chem. Soc. 1968, 90, 1651-1652.
39. Bodansky, M.; Bodansky, A. The Practice of Peptide Synthesis; Springer-Verlag: New York, 1984; pp 107-108.
40. Manson, D. L.; Musgrave, O. C. Condensation of Diketones with Aromatic Compounds. Part I. α-Diketones and Veratrole. J. Chem. Soc. 1963, 1011-1013.
41. Press, J. B. Deethylation of Aryl Ethyl Ethers by Boron Tribromide. Synth. Commun. 1979, 9, 407-410.